Can atrial fibrillation with a normal ventricular rate (normofrequent atrial fibrillation) cause or worsen heart failure with reduced ejection fraction (HFrEF)?

Can Normofrequent Atrial Fibrillation Drive HFrEF?

Yes, atrial fibrillation with a normal ventricular rate can absolutely cause or worsen heart failure with reduced ejection fraction, even without rapid ventricular response. The loss of coordinated atrial contraction, irregular ventricular filling, and underlying atrial-ventricular dyssynchrony can precipitate tachycardia-induced cardiomyopathy and perpetuate heart failure progression through mechanisms beyond rate alone 1.

The Bidirectional Relationship

AF and HFrEF interact in a vicious cycle where each condition perpetuates and exacerbates the other 1. AF is a strong independent risk factor for subsequent development of heart failure, with prevalence increasing from 4% in NYHA class I to 40% in NYHA class IV patients 1. This relationship operates through:

• Rate-dependent worsening of cardiac function (even at "normal" rates)
• Loss of atrial kick contributing 15-30% of cardiac output
• Myocardial fibrosis and structural remodeling
• Activation of neurohumoral vasoconstrictors
• Irregular ventricular filling patterns causing hemodynamic inefficiency

The Critical Concept: Tachycardia-Induced Cardiomyopathy

When a patient presents with newly detected HFrEF in the presence of AF—even with controlled rates—you must presume a rate-related or AF-mediated cardiomyopathy until proven otherwise 1. This is one of the few potentially reversible causes of heart failure.

Diagnostic Approach:

The guidelines are explicit: For patients with AF and rapid ventricular response causing or suspected of causing tachycardia-induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy (Class IIa-B) 2, 1.

Note the word "suspected"—you don't need to prove causation before treating. The temporal relationship and absence of other clear etiologies should trigger intervention.

Why "Normal" Rates Still Matter

The term "normofrequent" can be misleading. Several mechanisms explain why AF damages the heart even with acceptable resting heart rates:

1. Exercise intolerance: Resting rate control doesn't guarantee appropriate chronotropic response during activity 2, 1
2. Irregular rhythm itself: The beat-to-beat variability impairs ventricular filling efficiency regardless of average rate
3. Loss of AV synchrony: The absent atrial contribution reduces cardiac output by 15-30%
4. Subclinical tachycardia: Holter monitoring often reveals periods of inadequate rate control missed on spot checks

Assessment of heart rate control during exercise and adjustment of pharmacological treatment to keep the rate in the physiological range is useful in symptomatic patients during activity (Class I-C) 2, 1.

Treatment Strategy: The Paradigm Shift

Recent evidence has fundamentally changed how we approach AF in HFrEF:

For Suspected AF-Mediated Cardiomyopathy:

Two strategies are reasonable 1:

1. Rate control approach: Optimize rate control and reassess LVEF improvement over 3-6 months
2. Rhythm control approach: Initiate amiodarone and arrange cardioversion

Amiodarone has the advantage of being both an effective rate-control medication and the most effective antiarrhythmic with low proarrhythmia risk 1. Common practice involves starting amiodarone and cardioverting after one month.

For Established HFrEF with AF:

The evidence strongly favors rhythm control in selected patients:

• Catheter ablation has shown superiority over medical therapy in multiple RCTs, improving survival, quality of life, ventricular function, and reducing heart failure hospitalizations 3, 4, 5
• The CASTLE-AF trial demonstrated significant mortality reduction with ablation in HFrEF patients 3
• Current guidelines support catheter ablation as Class IIa-B for symptomatic AF in HFrEF 3
• Recent expert consensus suggests this may evolve to Class I indication with prognostic benefits regardless of symptoms 3

Rate Control Targets:

If pursuing rate control strategy:

• Lenient rate control (<110 bpm resting) is acceptable initially 6
• Stricter control is indicated if symptoms persist or tachycardia-mediated cardiomyopathy is suspected 6
• Beta-blockers are preferred agents given mortality benefits in HFrEF 1, 6
• Digoxin is effective adjunct for resting rate control 1

Common Pitfalls to Avoid

1. Assuming "rate-controlled" AF is benign: Even normofrequent AF can drive cardiomyopathy through non-rate mechanisms
2. Failing to assess exercise heart rate: Resting rates may be controlled while exercise rates remain excessive
3. Delaying rhythm control in appropriate candidates: Early ablation shows better outcomes than waiting for medical therapy failure 3
4. Overlooking reversibility: Always consider AF as potentially causative in new-onset HFrEF
5. Inadequate anticoagulation: Focus on rate/rhythm shouldn't overshadow stroke prevention

When to Suspect AF as the Driver

Consider AF as primary driver when:

• New-onset HFrEF temporally associated with AF onset
• No clear alternative etiology (no significant CAD, valvular disease, toxins)
• Younger patients with fewer comorbidities
• Non-ischemic cardiomyopathy pattern
• Persistent symptoms despite "adequate" rate control

The Bottom Line Algorithm

For new-onset HFrEF + AF:

1. Presume AF-mediated cardiomyopathy
2. Optimize GDMT for heart failure
3. Choose either aggressive rate control OR rhythm control (amiodarone + cardioversion)
4. Reassess LVEF at 3-6 months
5. If LVEF remains reduced, consider catheter ablation in appropriate candidates

For established HFrEF + symptomatic AF:

1. Optimize GDMT
2. Consider early catheter ablation (Class IIa-B) 3
3. If ablation unsuitable: optimize rate control with beta-blockers ± digoxin
4. If rate control fails: consider AV node ablation with biventricular pacing (Class IIa-B) 2, 1, 6

The evidence is clear: normofrequent AF is not benign in HFrEF—it can be both cause and consequence, and aggressive management targeting rhythm control shows mortality benefit in selected patients 3, 4, 5.